Grek et al. [1] demonstrated that therapeutic modulation of Cx43 by αCT1 preserves Cx43 at gap junction sites along the cell–cell membrane borders of breast cancer cells and enhances gap junction activity in functional assays. This evidence concerns the gene TRAF3IP2 and breast cancer.